medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2013, Número 1

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2013; 11 (1)


Vitamina D3 en dermatitis atópica: ¿Una nueva opción terapéutica?

Sánchez AK, Káram OM, Domínguez CJ, Rodríguez CAA, Contreras RJ

Idioma: Español
Referencias bibliográficas: 50
Paginas: 48-53
Archivo PDF: 170.51 Kb.


RESUMEN

Dermatitis atópica (DA) es una enfermedad crónica y recurrente que ocurre principalmente en la infancia, aunque su prevalencia se ha duplicado en las últimas décadas en los países industrializados afectando tanto a niños como adultos (15-30% y 2-10%,respectivamente).
La patogénesis de DA resulta de una compleja interacción de factores genéticos, inmunológicos, alteraciones de la barrera cutánea y el medio ambiente. Por este motivo, el tratamiento debe incluir hidratación de la piel, manejo farmacológico y eliminación de los factores exacerbantes como infecciones, irritantes y alérgenos.
Estudios recientes han demostrado que la conversión de 25-hidroxivitamina D a la forma activa 1,25-dihidroxivitamina D (vitamina D3) se lleva a cabo en queratinocitos y monocitos cutáneos. La vitamina D3 aumenta los niveles de catelicidinas, moléculas que activan y coordinan múltiples fases de las respuestas intrínseca y adaptativa del sistema inmune. Diversas investigaciones sugieren que los pacientes con DA están predispuestos a infecciones cutáneas debido a la baja producción de catelicidinas, que también son importantes péptidos antimicrobianos.
El presente trabajo tiene la finalidad de analizar las evidencias disponibles sobre la utilidad terapéutica de la vitamina D3 en pacientes con DA.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Leung DY, Eichenfield LF, Boguniewicz M. “Atopic dermatitis (atopic eczema)”. En: Fitzpatrick’s Dermatology in General Medicine. 6ª ed., Mc Graw Hill 2003: 1180-1893.

  2. Bieber T. “Atopic Dermatitis”. N Engl J Med 2008; 358: 1483-1494.

  3. Ezzat MHM, Hasan ZE and Shaheen KYA. “Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring”. J Eur Acad Dermatol Venereol 2011; 25(3): 334-339.

  4. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. “Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score”. Br J Dermatol 2007; 157: 645-648.

  5. Searing DA, Leung DY. “Vitamin D in atopic dermatitis, asthma and allergic diseases”. Immunol Allergy Clin North Am Aug 2010; 30(3): 397-409.

  6. Braff MH, Gallo RL. “Antimicrobial peptides: an essential component of the skin defensive barrier”. Curr Top Microbiol Immunol 2006; 306: 91-110.

  7. Braff MH, Zaiou M, Fierer J, Nizet V, Gallo RL. “Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens”. Infect Immun 2005; 73: 6771-6781.

  8. Di Nardo A, Vitiello A, Gallo RL. “Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide”. J Immunol 2003; 170: 2274-2278.

  9. Lee DY, Yamasaki K, Rudsil J, Zouboulis CC, Park GT, Yang JM, et al. “Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill Propionibacterium acnes”. J Invest Dermatol 2008; 17: 17.

  10. Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL. “Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin”. J Invest Dermatol 2002.

  11. Liu P, Stenger S, Li H, Wenzel L, Tan B, Krutzik S, et al. “Toll-like receptor triggering of a vitamin D mediated human antimicrobial response”. Science 2006; 311: 1770-1773.

  12. Schauber J, Dorschner R, Coda A, Büchau A, Liu P, Kiken D, et al. “Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism”. J Clin Invest 2007; 117: 803-811.

  13. Dombrowski Y, Peric M, Koglin S, Ruzicka T, Schauber J. “Control of cutaneous antimicrobial peptides by vitamin D3”. Arch Dermatol Res Aug 2010 Aug; 302(6): 401-408.

  14. Schauber J, Gallo RL. “Antimicrobial peptides and the skin immune defense system”. J Allergy Clin Immunol 2008; 122: 261-266.

  15. Braff MH, Bardan A, Nizet V, Gallo RL. “Cutaneous defense mechanisms by antimicrobial peptides”. J Invest Dermatol 2005; 125: 9-13.

  16. Lopez-Garcia B, Lee PH, Yamasaki K, Gallo RL. “Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection”. J Invest Dermatol 2005; 125: 108-115.

  17. Yang D, Chertov O, Oppenheim JJ. “Participation of mammalian defensins and cathelicidins in antimicrobial immunity: receptors and activities of human defensins and cathelicidin (LL-37)”. J Leukoc Biol 2001; 69: 691-697.

  18. Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, et al. “Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines”. J Invest Dermatol 2007; 127: 594-604.

  19. Jürgen S and Gallo R. “Antimicrobial peptides and the skin immune defense system”. J Allergy Clin Immunol Aug 2008; 122(2): 261-266.

  20. Siegfried Segaert. “Vitamin D regulation of Cathellicidin in the Skin: Toward a Renaissance of Vitamin D in Dermatology?”. J of Invest Dermatol 2008; 128: 773-775.

  21. Schauber J, Gallo RL. “Expanding the roles of antimicrobial peptides in skin: alarming and arming keratinocytes”. J Invest Dermatol 2007; 127: 510-512.

  22. Henry HL, Bouillon R, Norman AW, Gallagher JC, et al, “14th Vitamin D Workshop consensus on vitamin D nutritional guidelines”. J Steroid Biochem Mol Biol Jul 2010; 121(1-2): 4-6.

  23. Deeb KK, Trump DL, Johnson CS. “Vitamin D signalling pathways in cancer: potential for anticancer therapeutics”. Nature Reviews Cancer 2007; 7: 684-700.

  24. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. “Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes”. Am J Clin Nutr 2006; 84: 18-28.

  25. Somolinos Palencia J. “Niels Ryberg Finsen (1860-1904)”. Gac Méd Méx 1990; 126(6): 526.

  26. Segaert S. “Vitamin D regulation of Cathellicidin in the Skin: Toward a Renaissance of Vitamin D in Dermatology?”. J of Invest Dermatol 2008; 128: 773-775.

  27. Nagpal S, Na S and Rathnachalam R. “Noncalcemic actions of vitamin D receptor ligands”. Endocr Rev Aug 2005: 25(5): 62-87.

  28. Kimball S, El-Hajj G and Vieth R. “Vitamin D: A Growing Perspective”. Critical Reviews in Clinical Laboratory Sciences 2008; 45(4): 339-414.

  29. Miller J, Gallo RL. “Vitamin D and innate immunity”. Dermatol Ther 2010; 23: 13-22.

  30. Bäck O, Blomquist HK, Hernell O, Stenberg B. “Does vitamin D intake during infancy promote the development of atopic allergy?”. Acta Derm Venereol 2009; 89: 28-32.

  31. Camargo CA Jr, Rifas-Shiman SL, Litonjua AA, et al. “Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age”. Am J Clin Nutr 2007; 85: 788-795.

  32. Miyake Y, Sasaki S, Tanaka K, Hirota Y. “Dairy food, calcium, and vitamin D intake in pregnancy and wheeze and eczema in infants”. Eur Respir J 2010; 35: 1228-1234.

  33. Sidbury R, Sullivan AF, Thadhani RI, Camargo CA Jr. “Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study”. Br J Dermatol 2008; 159: 245-247.

  34. Peroni DG, Piacentini GL, Cametti E, et al. “Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children”. Br J Dermatol 2011; 164: 1078-1082.

  35. Schuessler M, Astecker N, Herzig G, et al. “Skin is an autonomous organ in synthesis, two-step activation and degradation of vitamin D(3): CYP27 in epidermis completes the set of essential vitamin D(3)-hydroxylases”. Steroids 2001; 66: 399-408.

  36. Schauber J, Dorschner RA, Yamasaki K, et al. “Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli”. Immunology 2006; 118: 509-519.

  37. Yamanaka K, Dimitroff CJ, Fuhlbrigge RC, et al. “Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression”. J Allergy Clin Immunol 2008; 121: 148-157.

  38. Yamanaka KI, Kakeda M, Kitagawa H, et al. “1,25-Dihydroxyvitamin D3 (tacalcitol) prevents skin T-cell infiltration”. Br J Dermatol 2010; 162: 1206-1215.

  39. Rigby WF, Stacy T, Fanger MW. “Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol)”. J Clin Invest 1984; 74: 1451-1455.

  40. Lemire JM, Archer DC, Beck L, Spiegelberg HL. “Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions”. J Nutr 1995; 125: S1704-8.

  41. Daniel C, Sartory NA, Zahn N, et al. “Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1 ⁄Th17 to a Th2 and regulatory T-cell profile”. J Pharmacol Exp Ther 2008; 324: 23-33.

  42. Oyoshi MK, He R, Kumar L, et al. “Cellular and molecular mechanisms in atopic dermatitis”. Adv Immunol 2009; 102: 135-226.

  43. Griffin MD, Xing N, Kumar R. “Vitamin D and its analogs as regulators of immune activation and antigen presentation”. Annu Rev Nutr 2003; 23: 117-145.

  44. Hata M, Kotol P, Jackson M, et al. “Administration of oral vitamin D induces cathelicidin production in atopic individuals”. J Allergy Clin Immunol 2008 Oct; 122(4): 829-831.

  45. Coates Me. “Requierments of different species for vitamins”. Proc Nutr Soc Sept 1988; 27 (2): 143-148.

  46. Vieth R, Bischoff-Ferrari H, Boucher BJ, et al. “The urgent need to recommend an intake of vitamin D that is effective”. Am J Clin Nutr 2007; 85: 649-650.

  47. Hackman KL, Gagnon C, Briscoe RK, et al. “Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting”. Med J Aust Jun 21, 2010; 192(12): 686-689.

  48. Javanbakht MH, Keshavarz SA, Djalali M, et al. “Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis”. J Dermatolog Treat Jun 2011; 22(3): 144-150.

  49. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. “Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes”. Am J Clin Nutr 2006; 84: 18-28.

  50. Aloia JF, Patel M, Dimaano R, et al. “Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration”. Am J Clin Nutr 2008; 87: 1952-1958.




2020     |     www.medigraphic.com